The next generation biopharmaceuticals

Affibody Announces Option Exercise by Biotest


Solna, Sweden, December 4, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug projects, today announced that its partner Biotest, a Germany-based biotherapeutic company, has exercised an option under the two companies’ ongoing collaboration.

Biotest has finalized the research phase of the research license and option agreement we originally signed in 2015 and based on the preclinical results decided to exercise its option. Biotest now receives exclusive rights for further development and commercialization of an innovative new haemophilia product”, said David Bejker, CEO of Affibody. “We are delighted with this decision, which demonstrates the innovative nature and competitive strength of our Affibody® technology.”

Preclinical results so far with the Albumod™ technology are very promising and we believe in its potential for the development of improved protein drugs in Biotest’s therapeutic areas such as haemophilia” says Dr Jörg Schüttrumpf, Senior Vice President Global Research Biotest.

Affibody will receive a license conversion fee and milestone payments as well as royalties.


Press release Biotest option – December 4 2018

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Interim Report January to March 2020 (May 15, 2020)
  • Interim Report January to June 2020 (August 21, 2020)
  • Interim Report January to September 2020 (November 13, 2020)
  • Year End Report 2020 (February 2021)